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Introduction: Topical intranasal drugs are widely prescribed for Chronic Rhinosinusitis (CRS), 
although delivery can vary with device type and droplet size. The study objective was to 
compare nebulized and sprayed droplet deposition in the paranasal sinuses and ostiomeatal 
complex (OMC) across multiple droplet sizes in CRS patients using computational fluid 
dynamics (CFD).  
Methods: Three-dimensional models of sinonasal cavities were constructed from computed 
tomography (CT) scans of three subjects with CRS refractory to medical therapy using imaging 
software. Assuming steady-state inspiratory airflow at resting rate, CFD was used to simulate 1-
120 μm sprayed droplet deposition in the left and right sinuses and OMC with spray nozzle 
positioning as in current nasal spray use instructions. Zero-velocity nebulization simulations 
were performed for 1-30 μm droplet sizes, maximal sinus and OMC deposition fractions 
(MSDF) were obtained, and sizes that achieved at least 50% of MSDF were identified. 
Nebulized MSDF was compared to sprayed droplet deposition. We also validated CFD 
framework through in vitro experiments.  
Results: Among nebulized droplet sizes, 11-14 μm droplets achieved at least 50% of MSDF in 
all six sinonasal cavities. Five of six sinonasal cavities had greater sinus and OMC deposition 
with nebulized droplets than with sprayed droplets at optimal sizes.  
Conclusions: Nebulized droplets may target the sinuses and OMC more effectively than sprayed 
particles at sizes achieving best deposition. Further studies are needed to confirm our preliminary 
findings. Several commercial nasal nebulizers have average particle sizes outside the optimal 
nebulized droplet size range found here, suggesting potential for product enhancement. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 Chronic rhinosinusitis (CRS) is a pervasive condition with a well-characterized, 
extensive public health burden.1 Symptoms include nasal obstruction, facial pressure, nasal 
discharge, and loss of smell. Additionally, CRS is associated with worsened quality of life, 
decreased productivity, and results in over $9 billion yearly in healthcare costs and more than 
$13 billion in societal costs in the United States.2-4 Functional endoscopic sinus surgery (FESS) 
is typically undertaken after medical therapy fails. Initial medical management includes 
antibiotics, nasal saline irrigations, and topical nasal or oral steroids.  
Topical treatment allows for direct drug delivery and reduction of potential systemic side 
effects, particularly for long-term use.5,6 Most patients are prescribed intranasal steroids in a 
spray formulation as part of their medical regimen. However, many patients with CRS eventually 
undergo surgery owing to a disease burden unresponsive to medical treatment. Intranasal spray 
delivery is based on many patient and drug-specific factors, and may be minimally effective if 
these factors are not optimized. Patient-specific factors include an understanding of head 
positioning, spray nozzle direction or positioning within the nasal cavity, and inhalation at time 
of spray. Drug-specific factors include drug particle size distribution, spray emission speed, and 
shot weight. Enhancing topical drug delivery to target diseased areas may result in better 
treatment outcomes and potentially reduce the need for surgery.  
Nebulizers may minimize several patient and drug-specific impediments to delivery that 
are encountered with nasal sprays, improving delivery to target sites. Since particles are 
aerosolized, nebulization permits widespread delivery throughout the nasal cavity including 
sinus ostia independent of device direction or angle encountered with nasal sprays. Additionally, 
most nebulizers use small particles which are likely to travel further to target sites instead of 
depositing in the anterior nose.7-10 Several types of nebulizers are commercially available, 
including active and passive flow nebulizers. Active flow devices include nebulizers with 
particle release at a given velocity, while passive nebulizers rely only on the negative pressure 
generated by inhalation.  
Although nebulizers may hold great potential, possibly reducing the need for surgery and 
associated morbidity or costs, little evidence exists to support their inclusion in the main CRS 
medical armamentarium. To date, primarily radiolabeled tracers or gamma scintigraphy methods 
have been used to assess nebulizer drug delivery to the sinuses.11-14 Only two prior studies have 
compared spray and nebulizer particle deposition in the sinonasal cavity demonstrating greater 
sinus deposition of nebulized particles.11,12 Computational fluid dynamics (CFD) methods enable 
simulation of airflow and particle delivery to the sinonasal cavity, and have been validated with 
physical models.15-19 Although CFD is emerging as the standard for assessing airflow and 
particle deposition, only one prior study has used CFD to analyze sinonasal nebulized particle 
deposition.17 The objective of this study was to compare nebulized and sprayed droplet 
deposition in the paranasal sinuses and ostiomeatal complex (OMC) across multiple droplet sizes 
in patients with CRS without nasal polyps using computational fluid dynamics (CFD). We 
hypothesize that sinus and OMC particle deposition will be higher with nebulizers compared to 
sprays.   
METHODS 
Patient Selection 
The study was approved by the University of North Carolina Institutional Review Board 
(IRB #10-0556). Pre-operative CT scans belonging to three individuals with CRS without nasal 
polyposis were used for the three-dimensional sinonasal reconstructions. Three patients (2 males, 
1 female) who were surgical candidates after failed medical management were specifically 
chosen to assess drug delivery with nebulizers compared to topical sprays in a diseased state with 
unaltered anatomy (Table 1). At the same visit, minute volumes were obtained during resting 
breathing using a portable respiratory inductive plethysmograph (LifeShirt®, VivoMetrics, San 
Diego, CA) and used for simulations.  
Three-Dimensional Model Development for CFD 
 The de-identified CT scans were imported into Mimics™ 18.0 (Materialize, Inc., 
Plymouth, MI, USA) imaging software. The airway was reconstructed using an imaging 
radiodensity threshold range of -1024 to -300 Houndsfield units with hand editing to ensure 
correct anatomy. The models were approved by multiple otolaryngologists for precision. 
Subsequently, the models were exported into the computer-aided design and meshing software 
ICEM-CFD™ 15.0 (ANSYS, Inc., Canonsburg, PA, USA). Boundary surfaces were created 
including nostrils and an outlet below the nasopharynx. The model was divided into anatomic 
regions including the anterior nose, main nasal cavity, middle turbinate, sinuses (maxillary, 
frontal, ethmoids, and sphenoid), ostiomeatal complex (OMC), and nasopharynx (Figure 1A-C). 
Based on previously validated methods, computational meshes of approximately 4 million 
tetrahedral cells with three 0.1-mm thick prism layers along airway walls were created (Figure 
1D).20,21 Mesh quality was verified by ensuring that if present, the number of distorted low-
quality elements was less than 40 (0.001%) .  
Airflow Simulations 
Steady-state, laminar, inspiratory airflow simulations were performed using Fluent™ 
(ANSYS, Inc., Canonsburg, PA, USA), at twice the resting breathing minute volume for each 
subject as measured at time of recruitment (Table 1). The numerical methods followed 
previously published work in the literature.17,22,23  
Spray and Nebulized Particle Deposition CFD Simulations  
Nasal sprays were simulated as series of solid-cone injections in Fluent™, one for each 
droplet diameter from 1 to 120 μm in 1μm increments, using a cone angle measured 3 cm above 
the sprayer (63.3°) and velocity based on patient-specific breathing rates. Injections were 
released from a point positioned 5 mm vertically into the nose from the nostril centroid with the 
head tilted forward at 22.5°. Deposition fractions were computed for each region in the models 
for each droplet size, using 5000 streams per injection.  
Nebulizers were simulated using the “surface” injection type in Fluent™. Ten thousand 
nostril surface release points were created. The authors were concerned that particles released too 
close to nostril edges in vivo may adhere to the nasal sill, columella, or anterior most aspect of 
the septum. To exclude these particles in the simulations so that deposition patterns in the 
computational study are not artificially inflated, a scale factor of 0.95 was used to 
circumferentially reduce the nostril surface used for particle release. Due to exclusion of the 5% 
circumferential surface area, a range of 8868 to 9868 particles (from the original 10,000 
spanning the original nostril surface) were released in the simulations. Nebulized droplet 
particles were simulated at zero velocity for monodisperse particle sizes ranging from 1-30 μm in 
the left and right sinuses and OMC. The simulations were performed in an upright head position.  
Validation Modeling 
An in vitro experiment was performed to validate nebulizer results. A 3-D printer was 
previously used to print the sinonasal airway and external nose for Subject 3. The nose was made 
from a pliable material with a similar texture to the external nose. The airway past the vestibule 
was made from a firmer material, representative of bony anatomy (Figure 2).  
Nebulized Aeresol Delivery for the in vitro Model 
 The 3-D printed model was exposed to a nebulized solution of sodium pertechnetate-99 
(99mTc) (10 millicuries in 0.4 mL of normal saline). We used a PARI LL jet nebulizer (Starnberg, 
Germany) modified by removing the lower third of the internal baffle to allow generation of 
aerosol particles (mass median aerodynamic diameter of 9.5 µm). Flow was drawn through the 
nebulizer and a single nostril (right side) of the model at a constant 6 L/min airflow in the 
inspiratory direction for approximately 100 seconds (Figure 2).  Under these conditions we 
estimated 200 µL may be delivered to the model, providing sufficient radioactivity for gamma 
scintigraphy scans (described below) while minimizing displacement of fluid on the internal 
model surfaces prior to scanning. 
Gamma Scintigraphy Scans  
 A gamma scintigraphy camera was used to record images of the models before and after 
administration of the nasal spray. Each scan, lasting three minutes, consisted of two images taken 
simultaneously, recording either Technetium or Americium energy levels. Three point sources of 
Americium were used as markers within the model to facilitate image processing. Five scans 
were taken for each experiment to examine deposition from the front and side of the model. Two 
background scans (front of the model and side of the model) were taken first. All “side” scans 
were taken on the right side of the model where the drug was administered. All front scans were 
performed without the soft nose attached. For side scans, the camera was rotated to 90 degrees 
and the side of the model was pressed flush to the camera. The head of the model was tilted 
forward at a 22.5 degree angle from upright. 
 After completion of the background scans, the nasal aerosol was administered into the 
indicated nostril as described above. Immediately following aerosol delivery, a scan was taken 
from the side, with the soft “anterior nose” still attached. The soft nose was then removed, and 
activity was measured. Another scan from the side was taken with the soft nose removed. The 
final scan was a front scan taken in the same manner as described for the background scan. 
Gamma Scintigraphy Image Processing 
 Processing of the scans was completed in ImageJ (National Institutes of Health). A region 
of interest (ROI) was constructed for each model, and for each view (front or side). Construction 
of each ROI was designed relative to the locations of the Americium markers. The side view was 
divided into vertical bins (columns/coronal planes) and horizontal bins (rows/transverse planes), 
as well as a bin for the filter. Data on the number of counts in each ROI was imported into 
Microsoft Excel 2017 and the difference between the scans after spray and the background scans 
was used to determine the amount of activity in each region due to the labeled nasal aerosol.  
CFD Simulation for Gamma Scintigraphy Comparison 
For CFD simulation, a round inlet was created in subject 3’s right nostril and used as the 
release surface for nebulized droplets. Nine micron sized particles were simulated, consistent 
with the nebulizer particle size used in the in vitro validation modeling. A total of 18,000 
particles were released from the surface for visualization and comparison to the in vitro 
experiment. All other simulations conditions were identical to the 1-30 micron particle size 
nebulizer simulations.  
Visualization and Statistical Analysis 
Visualization and analysis of results were performed in the post-processing software 
package FieldView™ 16 (Intelligent Light, Lyndhurst, PA). Sinus and OMC deposition fractions 
were defined as the number of total particles depositing in the sinuses and OMC divided by the 
total particles released. The particle size achieving maximal sinus and OMC deposition fractions 
(MSDF) was determined for both sprays and nebulizers. Sizes that achieved at least 50% of 
MSDF were also identified (Figure 3). Nebulized MSDF was compared to sprayed droplet 
deposition for the same size, and vice versa. Additionally, nebulizer and spray post-nasal 
penetration fraction was determined reflecting the fraction of droplets that traveled and deposited 
past the anterior nasal cavity. Total nebulizer and spray deposition fractions were also calculated 
for each particle size representing the fraction of particles that deposited in the sinonasal cavity 
(ie. did not escape through the nasopharynx). To statistically check the physical basis of the 
nebulized numerical predictions, we ran Spearman’s rank correlation test between the particle 
deposition fractions in the CFD simulations and the in vitro experiments. The test compared the 
deposition trends in the coronal, sagittal, and axial compartments of a representative model 
(Subject 3 RHS), and the reported numbers included Spearman’s rho and two-tailed p values. 
RESULTS 
Among nebulized particles, the droplet sizes achieving maximum sinus and OMC 
deposition (MSDF) among the six nasal sides ranged from 11 to 21 microns (Table 2). Particles 
within the range of 11-14 microns consistently achieved at least 50% of MSDF in all six 
sinonasal cavities (Table 2, Figure 4). The percent of nebulized droplets depositing past the 
anterior nasal cavity (defined as penetration) ranged from 55.6% to 96.7% at particle sizes 
achieving MSDF (Table 2).  
MSDF occurred at spray droplet sizes ranging from 4 to 13 microns among the six nasal 
sides (Table 2). No common particle size range was noted for particle sizes reaching at least 50% 
MSDF. Five of 6 nasal sides had overlap in the 10 to 11 micron particle range for 50% MSDF. 
The spray droplets percent penetration past the anterior nasal cavity ranged from 20.7% to 99.8% 
at particle sizes achieving MSDF (Table 2). 
When comparing sprayed and nebulized droplets in each sinonasal cavity, nebulizers 
droplets had greater MSDF compared to sprays in all but one case (subject 2 LHS, 23.1% 
nebulized vs. 35.3% sprayed, Table 2, Figure 5). The nebulized MSDF achieved in four of six 
cases was greater than the sinus and OMC deposition fraction or percentage of the same size 
spray particle; in one case, deposition was nearly identical, and the spray had greater deposition 
in the other case (Table 2).  
The distribution fraction for all particle sizes to the OMC region and maxillary, ethmoid, 
sphenoid, and frontal sinuses is represented in Figure 6 for each subject. The OMC region had 
the highest spray and nebulizer particle deposition in most cases across subjects with the 
exception of subject 3 who had high nebulized particle deposition to the ethmoid sinuses in 
addition to the OMC (Figure 6).  
Nebulizer and spray post-nasal penetration and total deposition fractions are shown in 
Figure 7. Larger sizes had lower penetration, depositing in the nasal cavity. This trend was more 
evident in sprays which had a larger particle size distribution (Figure 7). The plots of total 
deposition fractions and particle size were sigmoidal. Five micron or smaller nebulizer and spray 
particles had small total deposition fractions (0 to 0.2) and escaped through the nasopharynx; 
almost all larger particles deposited reaching a deposition fraction of 1 for the largest sizes 
(Figure 7).    
A visual comparison of the in silico (CFD) and in vitro (gamma scintigraphy) nebulized 
particle deposition for the purpose of CFD simulation validation is shown in Figure 8 for a 
representative model (subject 3, RHS). Similarly high deposition signals are visible at the 
anterior nose (Figure 8A) and the middle nasal cavity region in the vicinity of the OMC and at 
and below the level of the ethmoid sinuses (Figure 8B, 8C). The particle deposition fractions for 
CFD and gamma scintigraphy models are shown in Figure 9, representing significantly similar 
distribution across regions. For particle deposits in the coronal segments, the Spearman’s rank 
correlation test returned R = 0.83891 and the p value was 0.002 (Figure 9A, 9B). Comparison of 
the deposits in the sagittal segments resulted in R = 0.91539, with p value <0.001 (Figure 9C, 
9D). Finally, for particle deposits in the axial segments, the test gave R = 0.90696 and the p 
value was <0.001 (Figure 9E, 9F). Therefore by established standards (with all the two-tailed p 
values << 0.05), the congruity between the CFD simulated particle transport and the physical 
experiments in the 3-D solid replicate could be considered statistically significant. 
DISCUSSION 
 Our preliminary study highlights greater total OMC and sinus particle deposition from 
nebulizers compared to sprays in most cases. Additionally, there appeared to be a size 
‘preference’ between sprays and nebulizers. Ideal particle size for nebulizers remained in a more 
consistent range (between 10-14 microns) across patients, but fluctuated with a wider range for 
sprays. Furthermore, nebulizer particles of the same size as the spray particle sizes achieving 
MSDF had greater OMC and sinus deposition. Our group has previously shown that nebulizers 
deliver drugs more posteriorly in the nasal cavity compared to sprays when other anatomic 
changes such as septal deviation are present.24 However, this is the first study to use CFD to 
compare nebulized and spray particle delivery to the sinonasal cavity in CRS patients validated 
by gamma scintigraphy. Most prior studies assessing nebulizer deposition have used radiolabeled 
tracers and gamma scintigraphy as primary methods, which may yield less precise deposition 
data.11-14  
Inhaled particles deposit in different regions of the upper and lower airway based on their 
size.10,25 Our study confirmed prior research highlighting that particles that are 5 microns or less 
in size are more likely to deposit in the lungs, while those that are 10 microns or larger are more 
likely to deposit in the sinonasal cavity.9,10,24,25 Interestingly, our results highlight a common 
nebulizer particle deposition range of 10-14 microns, congruent with prior studies.24 On the other 
hand, optimal spray deposition ranges were highly variable. Furthermore, sprays included 
particles over 100 microns in size which tend to deposit anteriorly in the nasal vestibule due to 
their bulk and gravity, also verified in our study.  
Although the particle sizes in commercial sprays are optimal for rhinitis, the condition for 
which most intranasal steroid sprays are FDA-approved, these sprays are less than ideal 
treatment for sinusitis. In fact, one might postulate that patients may not be receiving maximal 
medical treatment prior to surgical consideration because of the inherent suboptimal nature of 
topical drug delivery to diseased areas. Particle size distributions could be altered in new sprays 
specifically manufactured for CRS. However, as reflected in our study, the broader range of 
effective sizes across different patients would add an obstacle to determining new particle 
distributions for sprays. From this standpoint, nebulizers are a better vehicle of drug delivery due 
to a consistent particle size range at peak deposition to the OMC and sinuses. Additionally, 
nebulizers cover more surface area due to greater and more widespread aerosolization.10,26 
However, many commercial nebulizers include particles that are less than 10 microns or larger 
than the optimal range in our study (Table 3), suggesting potential for product enhancement.  
Despite lack of evidence to date whether or not nebulizers are better treatment than 
sprays based on physical deposition characteristics, the decision not to use nebulizers in standard 
of care may be based on concern for affordability and patient compliance. Most nebulizers, with 
costs listed in Table 3, are more expensive than sinonasal sprays including Flonase and 
Nasacort which can be obtained over the counter. Additionally, sinonasal nebulizers may not 
be approved by many insurance companies. Nasal sprays are also more portable and easy to 
comply with, while nebulizers are bulkier (Table 3), and may require a plug-in set-up. Despite 
the inconveniences associated with nebulizers, if they are shown to be more effective treatment 
compared to sprays, they may enhance appropriate medical therapy, particularly benefiting 
patients with refractory symptoms.  
This pilot study was not without limitations. Firstly, we simulated a passive nebulizer 
with particle release at the nostril surface with inhalation. Therefore, our simulations do not 
represent the sinonasal nebulizers that have baseline actuation velocities and variable particle 
size distributions that may alter delivery. Our simulations did not mimic some unique nose 
pieces used with some nebulizers and their insertion depth in the nares, which may also influence 
particle deposition. However, we hope that this pilot study will serve as a baseline comparison 
for future analyses with modifications accounting for the diverse characteristics of current 
nebulizers. Lastly, our work focuses on pre-surgical CRS patients who have failed medical 
management in an effort to improve topical drug delivery and avoid surgery. Additional studies 
are needed to assess nebulized drug delivery in patients following FESS.  
CONCLUSIONS 
 In this pilot CFD study comparing particle deposition among single size nebulized and 
spray particles in patients who failed medical treatment, we determined that nebulized droplets 
may target the sinuses and OMC more effectively than sprayed particles at sizes achieving best 
deposition. The particle size range achieving the highest penetration of OMC and sinuses was 
consistent in the 10-14 microns range for nebulizers, but varied greatly for sprays. Additionally, 
this optimal nebulized droplet size range was different from those of several commercial nasal 
nebulizers, suggesting potential for product enhancement in the future.  
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Table 1. Subject Demographics 
Subject Sex Age Race BMI (kg/m2) 
Resting 
Minute 
Volume 
(L/Min) 
CRS 
Laterality 
Subject 1 M 70 Caucasian 24.8 9.23 Bilateral 
Subject 2 F 24 Caucasian 32.6 11.81 Bilateral 
Subject 3 M 41 Caucasian 25.3 12.17 Bilateral 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Nebulizer vs. Spray Particle Deposition 
  NEBULIZER SPRAY 
  Particl
e Size 
at 
MSDF 
(micro
ns) 
Fractional 
Depositio
n at 
MSDF (%) 
Fractional 
Deposition 
at Spray 
MSDF (%) 
 50% 
MSDF 
Particle 
Size 
Range 
(microns) 
Penetrate
d particles 
at MSDF 
particle 
size (%) 
Particle 
Size at 
MSDF 
(microns) 
Fractional 
Deposition 
at MSDF 
(%) 
Fractional 
Deposition 
at 
Nebulizer 
MSDF (%) 
 50% 
MSDF 
Particle 
Size 
Range 
(microns) 
Penetrated 
particles at 
MSDF 
particle 
size (%) 
Subject 1 
    
  
    
  
   LHS 13 14.6% 14.0% 10 to 18 96.5% 12 8.0% 8.2% 10 to 16 20.7% 
   RHS 21 3.7% 0.5% 9 to 22 55.6% 4 0.6% 2.1% 4 to 5, 9 
to 12 
99.8% 
Subject 2 
    
  
    
  
   LHS 11 23.1% 21.0% 9 to 14 92.2% 10 35.3% 60.5% 5 to 11 94.8% 
   RHS 15 14.6% 9.8% 7 to 20 82.1% 7 1.3% 14.7% 5 to 10 94.2% 
Subject 3 
    
  
    
  
   LHS 12 7.3% 7.3% 9 to 16 96.7% 12 6.0% 6.0% 10 to 18 24.7% 
   RHS 14 14.4% 14.4% 11 to 17 76.9% 13 8.4% 9.9% 11 to 15 76.9% 
 
 
Table 3. Commercial Nebulizers Available on the Market 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product 
Particle 
Size 
(µm) 
# of Nasal 
Applicator 
Prongs 
Compressor 
Dimensions Cost Device Image 
Nasoneb Sinus 
Therapy System: 
Model 7070 
21 1 W 6" x H 7" x D 5" $120 
  
Nasoneb Sinus 
Therapy System: 
Nasoneb II, 
Model 5070 
Not 
available 
online 
2 Not available online 
Not 
available 
online 
  
PARI SinuStar 3 2 5.75" x 7.5" x 5.5" $220 
  
PARI SINUS 
Pulsating 
Aerosol 
Compressor 
System 
3.2 1 W 7.6" x H 5.7" x D 5.9" $250 
  
 
Source website:  
http://nasoneb.com/in
dex.php?page=to_use   
Source website:  
http://nasoneb.co
m/index.php?page
=to_use   
 
Source website:  
https://justnebuli
zers.com/sinustar
-nasal-delivery-
system.html 
Source website:  
http://nebology.com/
pari-sinus-pulsating-
aerosol-compressor-
system.html 
Figure Legends 
Figure 1. Sinonasal 3-D Reconstructions and Mesh. A) Axial View. B) Coronal View. C) 
Sagittal View. Box denotes OMC region (green) with maxillary sinus removed for visualization. 
D. Tetrahedral mesh with three prism wide edges at nostril   
Figure 2. Validation experiment set-up. A) The nebulizer was positioned in a lead-lined box and 
connected to tubing with an inlet along the 3-D printed model’s right nostril surface and held in 
place with putty. A filter (green) represents the outlet. B, C, and D) In order to assess particle 
deposition to various regions of the sinonasal cavity, a grid method was used shown.  
Figure 3. Determination of Particles Meeting 50% Maximal Sinus and OMC Deposition 
Fraction (MSDF) criteria. After the MSDF and the particle size achieving MSDF were 
determined, all particles meeting half the MSDF or greater were included and reported as the size 
range meeting 50% MSDF. This example shows nebulizer particle deposition in subject 1 left 
hand side (LHS). 
Figure 4. Determination of Common Nebulizer Particle Size Range Across Subjects. Sinus and 
OMC deposition is shown for all subjects. The solid color lines represent the deposition fractions 
for each subject across particle sizes. The matched color dotted lines represent particle deposition 
fraction at which 50% maximal sinus and OMC deposition fraction (MSDF) was achieved for 
the corresponding subject. A common particle size range of 11-14 micron particles achieving at 
least 50% MSDF across all subjects (range represented within the vertical black lines).  
Figure 5. Nebulizer vs. Spray Particle Maximal Sinus and OMC Deposition Fraction (MSDF). 
All cases had greater nebulized particle MSDF, except for subject 2 left hand side (LHS) which 
exhibited greater spray particle deposition.  
Figure 6. Deposition Fractions for All Sinuses and OMC Across Subjects  
Figure 7. Post-Nasal Penetrance and Total Deposition Fractions. Post-nasal refers to deposition 
beyond the anterior nasal cavity region, beyond the internal nasal valve. Penetration fraction = 
fraction of particles depositing beyond the anterior nasal cavity.  
Figure 8. Validation of CFD Nebulized Particle Model. Left: Visualization of CFD nebulized 
particle deposition (blue = deposited particles). Right: Gamma scintigraphy-based nebulized 
particle deposition (bright signal = deposited particles). “Anterior nose” region is excluded in 
panels B and C to remove the high gamma scintigraphy anterior nose signal for better 
visualization of deposition in the regions of interest more posteriorly.  
Figure 9. Comparison of CFD and in vitro deposition patterns for validation. Coronal (A and B), 
sagittal (C and D), and axial (E and F) compartmental views are shown. The “anterior nose” 
region was excluded. Compartment labels correspond to consecutive sections of the models in 
each view as shown in Figure 2. 
 
 









